News & Events
Press Releases
Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference and Announces Additional Upcoming Conference Participations in Q1
Agomab Therapeutics NV (‘Agomab’) today announced that Tim Knotnerus, Chief Executive Officer, will present a company overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 8:00 a.m. ET (14:00 CET).
Agomab Expands Team with Reginald Brys as Head of Research and Maria Nichol as Head of IP
Agomab Therapeutics NV (‘Agomab’) today announced the expansion of its team with two key hires: Reginald Brys will join as Head of Research and Maria Nichol will become Head of Intellectual Property. Each brings more than 20 years of highly valuable experience in identifying and driving novel drug candidate development and international patent law and strategy, respectively.
Agomab Therapeutics Completes Acquisition of Origo Biopharma
Agomab Therapeutics NV (‘Agomab’) announced today the closing of the Origo Biopharma acquisition. The transaction, first announced on October 28th, 2021, combines Spanish biotech Origo Biopharma and its pipeline of organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway with Agomab’s hepatocyte growth factor (HGF)-targeting programs.
Agomab Therapeutics to Acquire Origo Biopharma
Agomab Therapeutics NV (‘Agomab’) announced today that it has entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders.
AgomAb Therapeutics Expands Senior Team with General Counsel and Head of Clinical Operations
AgomAb Therapeutics NV (‘AgomAb’) announced today the appointment of two new members to its senior team to further strengthen the company’s clinical, legal and corporate development capabilities. Ellen Lefever will join AgomAb as General Counsel, bringing extensive legal and transaction experience in the biotech
industry.
AgomAb Announces Two Oral Presentations at the EASL Liver Congress 2021
AgomAb Therapeutics N.V. (‘AgomAb’) announced today that two abstracts have been selected for oral presentations at the upcoming International Liver Congress™ hosted by the European Association for the Study of the Liver (EASL), held from June 23-26, 2021.
AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators
AgomAb Therapeutics N.V. announced today the closing of a $74 Million Series B financing round, led by Redmile Group with participation from Cormorant Capital and existing investors Pontifax, Andera Partners, Omnes Capital, Advent France Biotechnology and V-Bio Ventures.
AgomAb Therapeutics Closes Series A Extension Round with Additional Funding from Andera Partners
AgomAb Therapeutics N.V. (‘AgomAb’), a privately held Belgian biotherapeutics company developing agonistic antibodies for the regeneration of damaged tissues, announces today that it has secured additional financing in an extension to its Series A financing round from new investor Andera Partners.
AgomAb Therapeutics Completes €21m Series A Financing
AgomAb Therapeutics N.V., a privately held Belgian biotherapeutics company developing agonistic antibodies for regeneration of damaged tissues, announces today that it has secured €21m in a Series A financing round from a strong international investor syndicate.
Loading...
End of content
No more pages to load
Looking to connect with us?
William Blair Emerging Biotechnology Stars in Europe
July 19, 2022
July 19, 2022
LSX Investival Showcase 2022
November 14, 2022
London, UK
Jefferies London Healthcare Conference
November 15-17, 2022
London, UK
Events
AgomAb in the News
Video